Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte
WASHINGTON, DC — While Incyte and the founders of Flexus scrap in court over who owns the IDO1 technology that Bristol-Myers Squibb $BMY bought in a $1.25 billion deal a couple of years ago, Bristol-Myers is ready to start putting the early-stage data from a combination study with Opdivo on display.
Today at the SITC meeting, investigators say their ongoing Phase I/II study of the checkpoint drug Opdivo plus BMS-986205 produced some varying positive results for heavily pre-treated bladder (25 cases) and cervical cancer patients (22 patients).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
